Retatrutide is a synthetic peptide developed by Eli Lilly that acts as a triple agonist at the GIP, GLP-1, and glucagon receptors. The addition of glucagon receptor activity to the dual incretin scaffold is hypothesized to add an energy-expenditure component to the metabolic effects of incretin agonism.

It has been studied in Phase 2 clinical research for body weight reduction in adults with obesity and for glycemic control in type 2 diabetes, with results published in the New England Journal of Medicine.

It is used as a reference triple-agonist research compound in metabolic studies.

For research purposes only. Not for human consumption.